Search

everythinglearnresearchcommunity

for

Search:↓

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

Women with nonclassic congenital adrenal hyperplasia experience more sexual dysfunction and distress.

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder in women that can cause infertility and other health issues, and it may be improved by treatments that increase insulin sensitivity.

PCOS treatment should address both symptoms and metabolic risks, starting with lifestyle changes and possibly including medication.

Alternative treatments show promise for hair growth beyond traditional methods.

Women with polycystic ovary syndrome tend to have a longer distance between the clitoris and anus.

Polycystic ovary syndrome is found in 6.5% of unselected Caucasian women in Spain.

About 6.5% of young Caucasian women in Spain have polycystic ovary syndrome.

New hormonal contraceptives are safer, have fewer side effects, and offer health benefits for women.

New treatments for male hypogonadism are effective and should be personalized.

PCOS is a common hormonal disorder in women, treated with lifestyle changes and medications like hormonal contraceptives and metformin.

PCOS in teens is hard to diagnose, linked to genetics and lifestyle, and managed with weight loss and medication.

Anti-acne medications may work by reducing the activity of a protein involved in acne development.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

N-acetylcysteine may help treat uterine and placental issues in PCOS.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

New treatments for PCOS show promise, but no current medication treats all aspects of the condition.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Girls with PCOS during adolescence have a higher risk of developing type 2 diabetes, and early treatment can help manage this risk.

FPHL causes hair loss in women due to genetics and hormones; minoxidil and anti-androgens are treatments, and early intervention is advised.

Early diagnosis and treatment of PCOS is crucial to reduce emotional distress and health risks.

High fasting insulin levels in women with PCOS are linked to a higher risk of heart and metabolic problems.

Cannabinoid receptor-1 signaling is essential for the survival and growth of human hair follicle stem cells.

The study concluded that androstendione and DHEA are important for diagnosing high male hormone levels in women with excessive hair growth.

Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.